title: [Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlândia].
abstract: The introduction of multidrug therapy (WHO/MDT)-composed by the drugs dapsone, clofazimine and rifampicin has enabled the cure of Hansen's disease, however, the adverse effects of these drugs were not given priority by the health team. Aiming to determine MDT's adverse effects' magnitude and relate them to the non-adhesion of patients to the treatment, a study of 187 charts of patients treated with MDT from January of 1995 to May 2000, was carried out at a Health Center of the Federal University of Uberlândia. Side effects were recorded in 71 patients' charts. Among the 113 side effects found, 80 (70.7%) were related to dapsone, 7 (6.2%) were caused by rifampicin and 26 (20.5%) were attributed to clofazimine. These effects induced 28 (14.9%), patients to change the therapeutic scheme, representing 39.4% from the 71 patients with adverse effects. Throughout this study, the importance is discussed of considering MDT's adverse effects when training the health team to heighten the patient's adhesion to the treatment and thereby collaborating to eliminate Hansen's disease as a public health problem.
authors.affiliation: Departamento de Clínica Médica da Faculdade de Medicina da Universidade Federal de Uberlândia, Uberlândia, MG. imbgoulart@ufu.br
authors.forename: Isabela Maria Bernades
authors.initials: IM
authors.lastname: Goulart
authors.forename: Guilherme Leonel
authors.initials: GL
authors.lastname: Arbex
authors.forename: Marcus Hubaide
authors.initials: MH
authors.lastname: Carneiro
authors.forename: Mariana Scalia
authors.initials: MS
authors.lastname: Rodrigues
authors.forename: Rafael
authors.initials: R
authors.lastname: Gadia
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002991:Clofazimine / Q000008:administration & dosage / Q000009:adverse effects*; D003622:Dapsone / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D007918:Leprosy / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance / Q000706:statistics & numerical data; D010352:Patient Dropouts / Q000706:statistics & numerical data; D012189:Retrospective Studies; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D007917:Leprostatic Agents; D003622:Dapsone; D002991:Clofazimine; D012293:Rifampin